Of the @ patients receiving grazoprevir and elbasvir , six were excluded from the primary efficacy analysis for non-virological reasons ( death , lost-to-follow-up -LSB- n = @ -RSB- , non-compliance , patient withdrawal , and withdrawal by physician for violent behaviour ) .